Joan Mannick
Physician-scientist and CEO of Tornado Therapeutics focused on developing next-generation TORC1-selective mTOR inhibitors; known for pioneering human studies linking mTOR inhibition to improved aging immune function.
Best podcasts with Joan Mannick
Ranked by the Snipd community
Jan 17, 2024 • 1h 22min
Joan Mannick on Rapamycin Longevity Series | Turning down mTOR to young levels may be good for aging
Joan Mannick, physician-scientist and CEO of Tornado Therapeutics known for pioneering human mTOR/rapamycin studies. She discusses mTOR biology and its role in aging. Short-course, low-dose strategies to tune TORC1 without immunosuppression. Designing human trials that measure immune responses and translating rapalogs into safer, TORC1-selective drugs.
